JP2025510860A5 - - Google Patents

Info

Publication number
JP2025510860A5
JP2025510860A5 JP2024556788A JP2024556788A JP2025510860A5 JP 2025510860 A5 JP2025510860 A5 JP 2025510860A5 JP 2024556788 A JP2024556788 A JP 2024556788A JP 2024556788 A JP2024556788 A JP 2024556788A JP 2025510860 A5 JP2025510860 A5 JP 2025510860A5
Authority
JP
Japan
Prior art keywords
matrix tablet
tablet according
pharmaceutical
diseases
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510860A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/057792 external-priority patent/WO2023180576A1/en
Publication of JP2025510860A publication Critical patent/JP2025510860A/ja
Publication of JP2025510860A5 publication Critical patent/JP2025510860A5/ja
Pending legal-status Critical Current

Links

JP2024556788A 2022-03-25 2023-03-27 ブラジキニンb2受容体アンタゴニストを含む固体徐放性組成物 Pending JP2025510860A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164471.9 2022-03-25
EP22164471 2022-03-25
PCT/EP2023/057792 WO2023180576A1 (en) 2022-03-25 2023-03-27 Solid extended-release composition comprising bradykinin b2-receptor antagonists

Publications (2)

Publication Number Publication Date
JP2025510860A JP2025510860A (ja) 2025-04-15
JP2025510860A5 true JP2025510860A5 (enExample) 2026-04-06

Family

ID=80952430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556788A Pending JP2025510860A (ja) 2022-03-25 2023-03-27 ブラジキニンb2受容体アンタゴニストを含む固体徐放性組成物

Country Status (24)

Country Link
US (1) US20250228782A1 (enExample)
EP (2) EP4499039B1 (enExample)
JP (1) JP2025510860A (enExample)
KR (1) KR20240161195A (enExample)
CN (1) CN119136786A (enExample)
AU (1) AU2023240388A1 (enExample)
CA (1) CA3250834A1 (enExample)
CO (1) CO2024012885A2 (enExample)
DK (1) DK4499039T3 (enExample)
ES (1) ES3062435T3 (enExample)
FI (1) FI4499039T3 (enExample)
HR (1) HRP20260203T1 (enExample)
IL (1) IL315700A (enExample)
LT (1) LT4499039T (enExample)
MA (1) MA69210B1 (enExample)
MX (1) MX2024011704A (enExample)
PL (1) PL4499039T3 (enExample)
PT (1) PT4499039T (enExample)
RS (1) RS67776B1 (enExample)
SI (1) SI4499039T1 (enExample)
SM (1) SMT202600057T1 (enExample)
TW (1) TW202345810A (enExample)
WO (1) WO2023180576A1 (enExample)
ZA (1) ZA202408059B (enExample)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168667A (zh) 1994-10-27 1997-12-24 藤沢药品工业株式会社 用作缓激肽拮抗剂的吡啶并嘧啶酮,喹啉和稠合的n-杂环化合物
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
EP1085895A1 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Bradykinin antagonists
EP1123288A1 (en) 1998-10-21 2001-08-16 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
JP2005525398A (ja) 2002-04-10 2005-08-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
KR20150127718A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. B2-브라디키닌 수용체 매개 혈관부종의 치료 방법
SMT202200154T1 (it) * 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
AR118983A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
CA3198246A1 (en) * 2020-11-12 2022-05-19 Pharvaris Gmbh Prophylaxis and treatment of angioedema

Similar Documents

Publication Publication Date Title
US8658207B2 (en) Extended release tablet formulations of flibanserin and method for manufacturing the same
JP4242763B2 (ja) 速効性処方剤
JP2011513391A (ja) ミコフェノラートを含有する徐放性医薬組成物およびその方法
JP2007091758A5 (enExample)
CN103845335B (zh) 吉非替尼药物组合物及含有这一吉非替尼药物组合物的片剂
JP2026062756A (ja) ガンマ-ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
KR20090114332A (ko) 약제학적 제제
CN108289848A (zh) 包含urat1的有效抑制剂的药物组合物
JP7469293B2 (ja) Ag10の製剤
JP2022553313A5 (enExample)
CN104755074A (zh) 美金刚的药物组合物
CN102573911B (zh) 一种内含用以治疗神经退化性疾病的立即释出与长效释出药物的口服剂量配方
JP2011511818A (ja) フリバンセリンの製剤
KR20200010608A (ko) 서방성 토피라메이트 캡슐
WO2006080481A1 (ja) マルチプルユニット型経口徐放性製剤及びその製造方法
WO2017084486A1 (zh) 简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法
JP2025078766A (ja) ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法
JP2025512818A5 (enExample)
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
CN102740838B (zh) 卡维地洛控释剂
FI4499039T3 (fi) Bradykiniini b2 -reseptorin antagonisteja käsittävä kiinteä pitkävaikutteinen koostumus
WO2018211336A2 (en) Solid dosage form containing sorafenib tosylate
JP2007302688A5 (enExample)
KR20240105295A (ko) 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법
JP2012515765A (ja) 時間治療用医薬組成物